Article
Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein
Advancing Endometrial Cancer Care with Molecular Profiling
Summary
How molecular profiling of GOG258 is changing advanced endometrial cancer care—insights on POL-E, prognosis, and precision treatment.
In this compelling episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs is joined by innovators Dr. Angeles Alvarez Secord and Dr. Aine Clements to discuss high-impact data on endometrial cancer, focusing on the landmark GOG258 trial through the lens of modern molecular classification.
The trio explores how integrating single-gene testing for markers such as POL-E, mismatch repair, and p53 mutations is redefining “high risk,” shifting treatment strategies, and offering new hope for patients with advanced endometrial cancer. Hear first-hand about the years-long research journey, the challenges of trial design, and what practice-changing insights these findings bring to clinicians and patients, particularly regarding treatment de-escalation, prognosis, and precision oncology.
Tune in now to learn how GOG258’s molecular analysis is shaping the future of personalized medicine in uterine cancer care.
Related Topics
You May Also Like
Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein
Press Release
OVN Staff
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
Press Release
OVN Staff
Introducing OncologyVoiceNetwork.com
Article
A. Haslam, M.S. Kim, V. Prasad
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
Podcast
MSL Talk: Tom Caravela, Sarah Snyder
The Ideal Roadmap for New MSLs
Article
B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.